Orexo welcomes increased access to treatment for patients with opioid dependence in the US

Uppsala, Sweden – July 7, 2016 – Orexo AB applauds the Administration’s announcement yesterday to increase access to the treatment of opioid dependence in the US, by increasing the cap on the number of patients that can be treated by physicians from 100 to 275, starting 30 days after publication in the Federal Register. Additionally, we commend the strong bipartisan Congressional support of this announcement. We look forward to Congress passing additional legislation further supporting increased access to appropriate patient care. 

More than 5 million US citizens are misusing opioids and at least 2 million are opioid dependent. Today about 640,000 patients are in treatment with buprenorphine. Many struggle to find a qualified physician due to the patient cap which has been a significant hurdle in many regions of the US. In several instances, the lack of access to a qualified physician has led to a vicious cycle forcing patients to obtain their treatment on the street in a drug abusing environment perpetuating the risk of continued addiction.

Orexo strongly believes that medication assisted treatment with buprenorphine containing products, prescribed by a qualified physician should be used as part of a comprehensive treatment plan, which includes counseling and psychosocial support. With the initiative announced, opioid dependence treatment takes an important step towards open and affordable access to treatment in an appropriate clinical setting.

“I am encouraged by the initiative announced, which will be a significant change for many patients suffering from opioid dependence and save lives. For Orexo and our product Zubsolv® this change will be important for our continued sales and market share growth. I am proud of the incredible efforts our US team has made in Washington DC during the last 12 months to support the legislators and government with information and knowledge leading to this game changing decision for patients, physicians and for Orexo” said Nikolaj Sørensen, CEO and President of Orexo AB.  

For more information please contact:
Orexo AB (publ.)
Nikolaj Sørensen, CEO and President
Tel: +46 (0)18 780 88 00
email: ir@orexo.com

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden.

For more information about Orexo and Zubsolv, please visit www.orexo.com and www.zubsolv.com.

The information was submitted for publication at 8.00 am CET on July 7, 2016.

Tags:

About Us

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via selected partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees at year-end was 90. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.

Subscribe

Documents & Links